Immunotherapy has shown remarkable results with checkpoint inhibitors but lack of cancer-specific signposts may be preventing response in even more patients. Neoantigens may be the key. Read MoreDownload Attachment
MassBio® members enjoy a wide range of benefits including networking and educational events, savings through our Purchasing Consortium, business development and entrepreneurial support programs, public policy and advocacy engagement and economic development support. MassBio membership is the best way for you and your organization to connect with the world’s leading life sciences supercluster.
Click here to begin the member application process.